
Postpartum depression is a common and often devastating condition for new mothers, but the U.S. Food and Drug Administration on Tuesday approved the first drug to help combat it. The drug, Zulesso (brexanolone), is delivered via intravenous infusion. “Postpartum depression is a serious condition that, when severe, can be life-threatening,” noted the FDA’s Dr. Tiffany Farchione. “Women may experience thoughts about harming themselves or harming their child.” The condition “can also interfere with the maternal-infant bond,” added Farchione, who is acting director of the Division of Psychiatry Products in the agency’s Center for Drug Evaluation and Research. The FDA decision “marks the first time a drug has been specifically approved to treat postpartum depression, providing an important new treatment option,” she said in an agency statement. Psychiatrist Dr. Martha Wald agreed that women battling postpartum depression have long needed new options. “There is tremendous stigma around postpartum depression for women,” said Wald, a psychiatrist and psychoanalyst at Duke University, in Winston-Salem, N.C. “Many women experience great shame and feel inadequate as mothers if they struggle with depression at a time that is supposed to be joyous.” “Because of this stigma, many women choose to not seek help and endure great suffering in silence,” she said. “Postpartum depression affects 15 to 20 percent of the general population, and at least half of this group goes untreated.… read on >